



PRESS RELEASE

Published 25-02-2021

Asarina Pharma AB (publ) Q4 / Year End 2020 report released

Asarina Pharma CEO Peter Nordkild: “2020 was a turbulent, challenging year for all of us - yet at Asarina Pharma we begin 2021 with continued confidence in the high potential of our flagship compound Sepranolone. We are on schedule to publish our topline results for our Phase IIa Menstrual Migraine study in June 2021, and in the same month initiate our Phase IIa study in Tourette syndrome.”

FINANCIAL HIGHLIGHTS

- R&D costs reflecting termination of PMDD and CMC activities
- Staff costs lower due to headcount reduction
- Solid cash position at year-end

R&D HIGHLIGHTS

MENSTRUAL MIGRAINE

- Our Phase IIa Menstrual Migraine study reached full recruitment in October 2020 with 164 patients recruited
- The last patient was randomized on January 14, 2021
- We are on schedule to publish topline results in June 2021

TOURETTE SYNDROME

- In February 2021, new preclinical Tourette syndrome data again demonstrated that Tourette-like manifestations in mice are mediated by Allopregnanolone, and significantly suppressed by Sepranolone
- A preliminary, clean report from the juvenile tox study was received in mid-February confirming that we will be able to dose children and men with Sepranolone and Tourette syndrome following approval of our CTA from the Danish Medicines Agency
- We expect to submit a CTA to the Danish Medicines Agency for our upcoming Phase IIa Tourette syndrome study in early March
- We aim to initiate the study in June 2021

For further information, please contact:

Peter Nordkild, CEO

Phone: +45 25 47 16 46

E-mail: peter.nordkild@asarinapharma.com

Jakob Dynnes Hansen, CFO
Phone: +45 5132 3698
E-mail: jakob.dynnes@asarinapharma.com

Certified Adviser

Erik Penser Bank AB
Phone: +46 8-463 83 00
Mail: certifiedadviser@penser.se

About Asarina Pharma

We are a Swedish biotech company developing Sepranolone for allopregnanolone-related stress, menstrual and neurological disorders. Our product pipeline is built on over 40 years of research into allopregnanolone-related neurological disorders. With our new family of GAMSA compounds (GABA_A Modulating Steroid Antagonists) we aim to deliver a new generation of efficacious and safe drugs for still widely untreated neuroendocrinological conditions.

The information above was provided by the CEO of Asarina Pharma AB (publ), for publication on February 25, 08.00, 2021.